CD8A and neoplasm: The intricate interplay between tumor-infiltrating lymphocytes (TILs) and cancer’s genomic changes is strongly associated with clinical outcomes in OC patients, among which CD8+ cytotoxic T lymphocytes (CTLs) are the main players in mediating cytotoxic killing of cancer cells in most immunotherapy settings (Lheureux et al., 2019b; Desbois et al., 2020).